生物谷報(bào)道：法國(guó)研究人員9日在blood發(fā)表論文,，闡述了與血友病A相關(guān)的VIII因子相互作用影響其免疫周期,。
VIII因子(FVIII)作為凝血因子,，一種是在生理?xiàng)l件下自身產(chǎn)生的,，一種是作為血友病A的治療藥物而外源性輸入的,。FVIII與多種糖蛋白相互作用,，參與局部止血,。無(wú)論是內(nèi)源性的,，還是外源性的FVIII，最后都由免疫系統(tǒng)或清除細(xì)胞排除。這取決于多種因素,，如個(gè)體免疫情況,、不同時(shí)間、不同部位,、FVIII和相互作用因子含量,、親和性等。
研究者描述了FVIII生命周期中建立的不同相互作用,，特別是參與了先天性或后天性免疫應(yīng)答作用,，認(rèn)為這有助于理解FVIII動(dòng)力學(xué)，有助于理解長(zhǎng)效止血藥物無(wú)醫(yī)源性免疫原性,。（生物谷www.bioon.com）
生物谷推薦原始出處：
Blood. 2008 May 9; : 18469198 (P,S,E,B,D)
Dynamics of factor VIII interactions determine its immunological fate in hemophilia A.
Sebastien Lacroix-Desmazes, Ana-Maria Navarrete, Sebastien Andre, Jagadeesh Bayry, Srinivas V Kaveri, Suryasarathi Dasgupta
INSERM UMR S 872, Universite Pierre et Marie Curie, Paris, France.
Pro-coagulant factor VIII (FVIII) is either produced endogenously under physiological conditions, or administered exogenously as a therapeutic hemostatic drug in patients with hemophilia A. In the circulation, FVIII interacts with a multitude of glycoproteins, and may be used for coagulation at the sites of bleeding, eliminated by scavenger cells or be processed by the immune system, either as a self-constituent or as a foreign antigen. The fate of FVIII is dictated by the immune status of the individual, the location of FVIII in the body at a given time-point, and the inflammatory microenvironment. It also depends on the local concentration of FVIII and of each interacting partner, and on the affinity of the respective interactions. FVIII, by virtue of its promiscuity, thus constitutes the core of a dynamic network that links the coagulation cascade, cells of the immune system and, presumably, the inflammatory compartment. We describe the different interactions that FVIII is prone to establish during its life cycle, with a special focus on players of the innate and adaptive immune response. Lessons can be learned from understanding the dynamics of FVIII interactions; lessons that should pave the way to the conception of long-lasting hemostatic drugs devoid of iatrogenic immunogenicity.
